Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer
Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor‐2 (HER2)‐positive breast cancer. However, primary and acquired resistance to trastuzumab remains a significant problem. Pertuzumab, a humanize...
Saved in:
| Published in: | Pharmacotherapy Vol. 34; no. 1; pp. 60 - 71 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Boston, MA
Blackwell Publishing Ltd
01-01-2014
Pharmacotherapy Wiley Subscription Services, Inc |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor‐2 (HER2)‐positive breast cancer. However, primary and acquired resistance to trastuzumab remains a significant problem. Pertuzumab, a humanized monoclonal antibody that binds to a domain of the HER2 receptor separate from trastuzumab, may have the potential to overcome trastuzumab resistance. Clinical trials have shown that pertuzumab can be effectively combined with other biologic therapy or chemotherapy in patients with metastatic HER2‐positive breast cancer. Pertuzumab is relatively well tolerated with minimal increases in hematologic and cardiac toxicity observed when added to trastuzumab and/or docetaxel. In addition to becoming the standard of care in combination with docetaxel and trastuzumab in patients with newly diagnosed HER2‐positive metastatic breast cancer, clinical trials continue to evaluate pertuzumab in combination with other targeted therapy, chemotherapy, and in patients with early stage breast cancer. These trials will help to further determine the role of pertuzumab in the treatment of HER2‐positive breast cancer. |
|---|---|
| AbstractList | Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. However, primary and acquired resistance to trastuzumab remains a significant problem. Pertuzumab, a humanized monoclonal antibody that binds to a domain of the HER2 receptor separate from trastuzumab, may have the potential to overcome trastuzumab resistance. Clinical trials have shown that pertuzumab can be effectively combined with other biologic therapy or chemotherapy in patients with metastatic HER2-positive breast cancer. Pertuzumab is relatively well tolerated with minimal increases in hematologic and cardiac toxicity observed when added to trastuzumab and/or docetaxel. In addition to becoming the standard of care in combination with docetaxel and trastuzumab in patients with newly diagnosed HER2-positive metastatic breast cancer, clinical trials continue to evaluate pertuzumab in combination with other targeted therapy, chemotherapy, and in patients with early stage breast cancer. These trials will help to further determine the role of pertuzumab in the treatment of HER2-positive breast cancer. Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. However, primary and acquired resistance to trastuzumab remains a significant problem. Pertuzumab, a humanized monoclonal antibody that binds to a domain of the HER2 receptor separate from trastuzumab, may have the potential to overcome trastuzumab resistance. Clinical trials have shown that pertuzumab can be effectively combined with other biologic therapy or chemotherapy in patients with metastatic HER2-positive breast cancer. Pertuzumab is relatively well tolerated with minimal increases in hematologic and cardiac toxicity observed when added to trastuzumab and/or docetaxel. In addition to becoming the standard of care in combination with docetaxel and trastuzumab in patients with newly diagnosed HER2-positive metastatic breast cancer, clinical trials continue to evaluate pertuzumab in combination with other targeted therapy, chemotherapy, and in patients with early stage breast cancer. These trials will help to further determine the role of pertuzumab in the treatment of HER2-positive breast cancer. [PUBLICATION ABSTRACT] |
| Author | Malenfant, Stephanie J. Eckmann, Karen R. Barnett, Chad M. |
| Author_xml | – sequence: 1 givenname: Stephanie J. surname: Malenfant fullname: Malenfant, Stephanie J. organization: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Texas, Houston – sequence: 2 givenname: Karen R. surname: Eckmann fullname: Eckmann, Karen R. organization: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Texas, Houston – sequence: 3 givenname: Chad M. surname: Barnett fullname: Barnett, Chad M. email: cmbarnet@mdanderson.org organization: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Texas, Houston |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28157233$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23918291$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10E1vEzEQBmALFdG0cOAPIEuIA4dtZ-z98HJL05KA0jYqQXCzbO-Ybkmyqb1LCb-ejRLKqSfP4Zl55feIHayaFTH2GuEEAcTp-taEE5RSPWMDVEWWlIjpARuAKIoEANQhO4rxrqeYp-IFOxSyRCVKHLDLGYW2-9Mtjf3Ah_yKHvjchB_UUsXntxTMesN9E_jk4kYksybWbf2L-CW1JramrR0_C9SPfGRWjsJL9tybRaRX-_eYff14MR9Nkun1-NNoOE1cKlAlaQqFAimrPEdvqxQRHUKOQCC8VzatnJXegLUSCzDWgUOqILcqzRV6IY_Z293ddWjuO4qtvmu6sOojNWZ5lmFWlqpX73fKhSbGQF6vQ700YaMR9LY4vS1Ob4vr7Zv9xc4uqXqU_5rqwbs9MNGZhQ_9h-v43ynMCiFl70537qFe0ObpRD2bDG_20cluo44t_X7cMOGnzgtZZPrb1Vh_P_tyPp59Hump_AueFZOt |
| CODEN | PHPYDQ |
| CitedBy_id | crossref_primary_10_1002_adhm_201400222 crossref_primary_10_1016_j_bbrep_2023_101588 crossref_primary_10_3390_molecules26206253 crossref_primary_10_1093_bioinformatics_btac429 crossref_primary_10_1186_s12935_021_02182_6 crossref_primary_10_1002_bkcs_10358 crossref_primary_10_1007_s12609_019_00332_4 crossref_primary_10_3892_ol_2018_8698 crossref_primary_10_1038_s41523_018_0072_8 crossref_primary_10_1111_ajco_12500 crossref_primary_10_1111_cpr_12266 crossref_primary_10_3892_or_2015_4528 crossref_primary_10_3892_or_2015_4509 crossref_primary_10_1016_j_tips_2016_09_007 |
| Cites_doi | 10.1200/JCO.2011.37.4207 10.1200/JCO.2005.03.184 10.1158/0008-5472.SABCS12-P5-18-20 10.1158/1078-0432.CCR-07-4636 10.1038/sj.onc.1210379 10.1200/JCO.2002.20.3.719 10.1016/j.bbrc.2004.04.150 10.1038/nrc2656 10.1016/S1535-6108(04)00083-2 10.1186/bcr919 10.1056/NEJMoa1113216 10.1200/JCO.2007.11.6699 10.4161/cbt.11.9.15045 10.1634/theoncologist.2008-0230 10.1158/0008-5472.473.65.2 10.1158/0008-5472.SABCS11-S5-6 10.1200/JCO.2009.24.2024 10.1016/S1535-6108(02)00097-1 10.1200/JCO.2006.09.2775 10.1002/cncr.22885 10.1186/bcr927 10.1074/mcp.R400001-MCP200 10.1128/MCB.16.10.5276 10.1200/JCO.2009.24.1661 10.1038/35052073 10.1016/S1470-2045(11)70336-9 10.1158/0008-5472.SABCS-09-5090 10.1200/JCO.2011.40.2545 10.1158/0008-5472.SABCS12-S5-1 10.1002/j.1460-2075.1996.tb00356.x 10.1158/0008-5472.SABCS-09-5060 10.1056/NEJMra043186 10.1007/s11095-006-0205-x 10.1007/s00280-008-0882-8 10.1158/0008-5472.SABCS12-P5-18-26 10.1200/JCO.2009.25.8707 10.1093/jnci/93.24.1852 10.1038/nature01392 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V 10.1016/j.ccr.2004.06.022 10.1200/JCO.2008.21.4437 10.1093/annonc/mdl475 10.1093/annonc/mdr294 10.1093/jjco/hyp006 10.1158/0008-5472.CAN-03-3856 |
| ContentType | Journal Article |
| Copyright | 2013 Pharmacotherapy Publications, Inc. 2015 INIST-CNRS |
| Copyright_xml | – notice: 2013 Pharmacotherapy Publications, Inc. – notice: 2015 INIST-CNRS |
| DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. |
| DOI | 10.1002/phar.1338 |
| DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts |
| DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1875-9114 |
| EndPage | 71 |
| ExternalDocumentID | 3443426791 10_1002_phar_1338 23918291 28157233 PHAR1338 ark_67375_WNG_XBSDGPJC_L |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .GJ .Y3 05W 0R~ 0VX 123 1CY 1OB 1OC 31~ 33P 34G 39C 3SF 4.4 50Z 52U 52V 53G 5RE 8-0 8-1 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAXRX AAYOK AAZKR ABCUV ABJNI ABLJU ABOCM ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BRXPI BSCLL CS3 DCZOG DPXWK DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F5P FEDTE FUBAC G-S GODZA GWYGA H.X HGLYW HVGLF HZ~ J5H KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MJL MK0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N04 N05 NF~ O66 O9- P2P P2W PALCI PQQKQ Q.N QB0 R.K RIWAO RJQFR ROL SAMSI SJN SUPJJ SV3 TUS TWZ UDS WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR YCJ ZGI ZXP ZZTAW ~WT 08R 8W4 AAVGM ABFLS ABHUG ABIQD ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS C45 IQODW PQEST CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7QP 7TK K9. |
| ID | FETCH-LOGICAL-c4218-44078033d661fbd4111c10610e02ff8b4dcb3fa0bb3170abc0c1ed06b84681f23 |
| IEDL.DBID | 33P |
| ISSN | 0277-0008 |
| IngestDate | Tue Nov 19 05:55:16 EST 2024 Thu Nov 21 22:21:59 EST 2024 Sat Sep 28 07:55:03 EDT 2024 Fri Nov 25 01:09:10 EST 2022 Sat Aug 24 00:59:15 EDT 2024 Wed Oct 30 09:56:31 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Human Breast disease Targeted therapy erbB2 Gene Breast cancer Monoclonal antibody Malignant tumor Metastasis Epidermal growth factor receptor Human Epidermal growth factor Receptor 2 Immunomodulator Mammary gland diseases Growth factor receptor Treatment Pertuzumab C-Onc gene human epidermal growth factor receptor Advanced stage HER2 Protooncogene Cancer breast cancer pertuzumab |
| Language | English |
| License | CC BY 4.0 2013 Pharmacotherapy Publications, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4218-44078033d661fbd4111c10610e02ff8b4dcb3fa0bb3170abc0c1ed06b84681f23 |
| Notes | istex:04171CF38C6E25D801CFB2A5B4336B7CC9FD7212 ark:/67375/WNG-XBSDGPJC-L ArticleID:PHAR1338 |
| PMID | 23918291 |
| PQID | 1565515998 |
| PQPubID | 2032445 |
| PageCount | 12 |
| ParticipantIDs | proquest_journals_1565515998 crossref_primary_10_1002_phar_1338 pubmed_primary_23918291 pascalfrancis_primary_28157233 wiley_primary_10_1002_phar_1338_PHAR1338 istex_primary_ark_67375_WNG_XBSDGPJC_L |
| PublicationCentury | 2000 |
| PublicationDate | 2014-01 January 2014 2014 2014-Jan 2014-01-00 20140101 |
| PublicationDateYYYYMMDD | 2014-01-01 |
| PublicationDate_xml | – month: 01 year: 2014 text: 2014-01 |
| PublicationDecade | 2010 |
| PublicationPlace | Boston, MA |
| PublicationPlace_xml | – name: Boston, MA – name: United States – name: Hoboken |
| PublicationTitle | Pharmacotherapy |
| PublicationTitleAlternate | Pharmacotherapy |
| PublicationYear | 2014 |
| Publisher | Blackwell Publishing Ltd Pharmacotherapy Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Pharmacotherapy – name: Wiley Subscription Services, Inc |
| References | Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 2004;6:204-10. Niculescu-Duvaz I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther 2010;12:350-60. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007;26:3637-43. Nagata Y, Lan K-H, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19. Olson EM. Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. J Clin Oncol 2012;30:1712-4. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30. Ishida T, Kiba T, Takeda M, et al. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol 2009;64:361-9. Genentech Inc. PERJETA (pertuzumab) injection for intravenous administration package insert. South San Francisco, CA; 2012. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43. Gianni L, Llado A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:1131-7. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-64. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965-72. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28. GlaxoSmithKline. TYKERB (Lapatinib) tablet for oral administration package insert. Research Triangle Park, NC; 2012. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7. Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14:2710-6. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011;11:793-800. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006;23:1275-84. Lenihan D, Suter T, Brammer M, et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012;23:791-800. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:1594-600. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44. Wolff AC, Hammond MEH, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2006;25:118-45. Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 2009;39:260-6. Nagy P, Friedländer E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82. Carraway H, Hidalgo M. Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004;6:219-24. Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays 1998;20:41-8. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-7. Genentech Inc. HERCEPTIN (Trastuzumab) injection for intravenous administration package insert. South San Francisco, CA; 2010. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature Rev Mol Cell Biol 2001;2:127-37. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75. 2010; 12 2007; 18 2001; 93 2004; 64 2009; 64 2012; 366 2012 2011 2010 2009 2008; 14 2004; 3 2002; 2 2004; 6 2011; 11 2004; 5 2005; 65 2012; 13 1996; 16 1998; 20 1996; 15 2005; 23 2012; 30 2007; 357 2009; 14 2006; 23 2002; 20 2010; 28 2007; 110 2006; 25 2008; 26 2009; 9 2001; 2 2003; 421 2012; 23 2007; 26 2004; 319 2009; 39 10.1002/phar.1338-BIB0044|phar1338-cit-0044 Baselga (10.1002/phar.1338-BIB0039|phar1338-cit-0039) 2012; 366 Ng (10.1002/phar.1338-BIB0034|phar1338-cit-0034) 2006; 23 Yarden (10.1002/phar.1338-BIB0005|phar1338-cit-0005) 2001; 2 Franklin (10.1002/phar.1338-BIB0007|phar1338-cit-0007) 2004; 5 Agus (10.1002/phar.1338-BIB0035|phar1338-cit-0035) 2002; 2 Lu (10.1002/phar.1338-BIB0027|phar1338-cit-0027) 2001; 93 Wolff (10.1002/phar.1338-BIB0001|phar1338-cit-0001) 2006; 25 Nagy (10.1002/phar.1338-BIB0029|phar1338-cit-0029) 2005; 65 Ross (10.1002/phar.1338-BIB0004|phar1338-cit-0004) 2004; 3 Blackwell (10.1002/phar.1338-BIB0009|phar1338-cit-0009) 2010; 28 Yamamoto (10.1002/phar.1338-BIB0042|phar1338-cit-0042) 2009; 39 10.1002/phar.1338-BIB0008|phar1338-cit-0008 Nahta (10.1002/phar.1338-BIB0003|phar1338-cit-0003) 2007; 26 Gianni (10.1002/phar.1338-BIB0041|phar1338-cit-0041) 2010; 28 Cho (10.1002/phar.1338-BIB0033|phar1338-cit-0033) 2003; 421 Vogel (10.1002/phar.1338-BIB0020|phar1338-cit-0020) 2002; 20 Carraway (10.1002/phar.1338-BIB0049|phar1338-cit-0049) 2004; 6 Roskoski (10.1002/phar.1338-BIB0014|phar1338-cit-0014) 2004; 319 Baselga (10.1002/phar.1338-BIB0006|phar1338-cit-0006) 2009; 9 Nagata (10.1002/phar.1338-BIB0026|phar1338-cit-0026) 2004; 6 10.1002/phar.1338-BIB0043|phar1338-cit-0043 Burstein (10.1002/phar.1338-BIB0022|phar1338-cit-0022) 2007; 110 Gianni (10.1002/phar.1338-BIB0045|phar1338-cit-0045) 2012; 13 Karunagaran (10.1002/phar.1338-BIB0016|phar1338-cit-0016) 1996; 15 Genentech Inc. (10.1002/phar.1338-BIB0018|phar1338-cit-0018) 2010 Garrett (10.1002/phar.1338-BIB0030|phar1338-cit-0030) 2011; 11 Agus (10.1002/phar.1338-BIB0031|phar1338-cit-0031) 2005; 23 Lin (10.1002/phar.1338-BIB0012|phar1338-cit-0012) 2004; 6 10.1002/phar.1338-BIB0024|phar1338-cit-0024 GlaxoSmithKline (10.1002/phar.1338-BIB0019|phar1338-cit-0019) 2012 Cortes (10.1002/phar.1338-BIB0038|phar1338-cit-0038) 2012; 30 Tzahar (10.1002/phar.1338-BIB0015|phar1338-cit-0015) 1996; 16 Genentech Inc. (10.1002/phar.1338-BIB0032|phar1338-cit-0032) 2012 Baselga (10.1002/phar.1338-BIB0036|phar1338-cit-0036) 2010; 28 Seidman (10.1002/phar.1338-BIB0021|phar1338-cit-0021) 2008; 26 Lenihan (10.1002/phar.1338-BIB0047|phar1338-cit-0047) 2012; 23 Hudis (10.1002/phar.1338-BIB0017|phar1338-cit-0017) 2007; 357 Ross (10.1002/phar.1338-BIB0002|phar1338-cit-0002) 2009; 14 Olson (10.1002/phar.1338-BIB0050|phar1338-cit-0050) 2012; 30 Niculescu-Duvaz (10.1002/phar.1338-BIB0048|phar1338-cit-0048) 2010; 12 10.1002/phar.1338-BIB0040|phar1338-cit-0040 Burstein (10.1002/phar.1338-BIB0010|phar1338-cit-0010) 2010; 28 10.1002/phar.1338-BIB0011|phar1338-cit-0011 10.1002/phar.1338-BIB0046|phar1338-cit-0046 Ishida (10.1002/phar.1338-BIB0023|phar1338-cit-0023) 2009; 64 Valabrega (10.1002/phar.1338-BIB0025|phar1338-cit-0025) 2007; 18 Portera (10.1002/phar.1338-BIB0037|phar1338-cit-0037) 2008; 14 Nahta (10.1002/phar.1338-BIB0028|phar1338-cit-0028) 2004; 64 Riese (10.1002/phar.1338-BIB0013|phar1338-cit-0013) 1998; 20 |
| References_xml | – volume: 13 start-page: 25 year: 2012 end-page: 32 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2‐positive breast cancer (NeoSphere): a randomised multicentre, open‐label, phase 2 trial publication-title: Lancet Oncol – year: 2011 – volume: 23 start-page: 791 year: 2012 end-page: 800 article-title: Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab publication-title: Ann Oncol – year: 2009 – volume: 65 start-page: 473 year: 2005 end-page: 82 article-title: Decreased accessibility and lack of activation of ErbB2 in JIMT‐1, a herceptin‐resistant, MUC4‐expressing breast cancer cell line publication-title: Cancer Res – volume: 16 start-page: 5276 year: 1996 end-page: 87 article-title: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor publication-title: Mol Cell Biol – volume: 23 start-page: 2534 year: 2005 end-page: 43 article-title: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer publication-title: J Clin Oncol – volume: 9 start-page: 463 year: 2009 end-page: 75 article-title: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 publication-title: Nat Rev Cancer – volume: 366 start-page: 109 year: 2012 end-page: 19 article-title: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer publication-title: N Engl J Med – volume: 2 start-page: 127 year: 2002 end-page: 37 article-title: Targeting ligand‐activated ErbB2 signaling inhibits breast and prostate tumor growth publication-title: Cancer Cell – volume: 93 start-page: 1852 year: 2001 end-page: 7 article-title: Insulin‐like growth factor‐I receptor signaling and resistance to trastuzumab (Herceptin) publication-title: J Natl Cancer Inst – volume: 28 start-page: 1138 year: 2010 end-page: 44 article-title: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2‐positive metastatic breast cancer that progressed during prior trastuzumab therapy publication-title: J Clin Oncol – volume: 6 start-page: 219 year: 2004 end-page: 24 article-title: Mammalian target of rapamycin (mTOR) antagonists publication-title: Breast Cancer Res – volume: 2 start-page: 127 year: 2001 end-page: 37 article-title: Untangling the ErbB signalling network publication-title: Nature Rev Mol Cell Biol – volume: 25 start-page: 118 year: 2006 end-page: 45 article-title: American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer publication-title: J Clin Oncol – volume: 30 start-page: 1594 year: 2012 end-page: 600 article-title: Pertuzumab monotherapy after trastuzumab‐based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2‐positive breast cancer publication-title: J Clin Oncol – volume: 20 start-page: 41 year: 1998 end-page: 8 article-title: Specificity within the EGF family/ErbB receptor family signaling network publication-title: BioEssays – volume: 28 start-page: 1124 year: 2010 end-page: 30 article-title: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2‐positive, trastuzumab‐refractory metastatic breast cancer publication-title: J Clin Oncol – volume: 6 start-page: 117 year: 2004 end-page: 27 article-title: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients publication-title: Cancer Cell – volume: 3 start-page: 379 year: 2004 end-page: 98 article-title: Targeted therapy in breast cancer: the HER‐2/neu gene and protein publication-title: Mol Cell Proteomics – volume: 5 start-page: 317 year: 2004 end-page: 28 article-title: Insights into ErbB signaling from the structure of the ErbB2‐pertuzumab complex publication-title: Cancer Cell – volume: 421 start-page: 756 year: 2003 end-page: 60 article-title: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab publication-title: Nature – volume: 11 start-page: 793 year: 2011 end-page: 800 article-title: Resistance to HER2‐directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications publication-title: Cancer Biol Ther – volume: 64 start-page: 361 year: 2009 end-page: 9 article-title: Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes publication-title: Cancer Chemother Pharmacol – volume: 357 start-page: 39 year: 2007 end-page: 51 article-title: Trastuzumab–mechanism of action and use in clinical practice publication-title: N Engl J Med – year: 2010 – year: 2012 – volume: 28 start-page: 1301 year: 2010 end-page: 7 article-title: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2‐positive breast cancer publication-title: J Clin Oncol – volume: 26 start-page: 3637 year: 2007 end-page: 43 article-title: Trastuzumab: triumphs and tribulations publication-title: Oncogene – volume: 26 start-page: 1642 year: 2008 end-page: 9 article-title: Randomized phase III trial of weekly compared with every‐3‐weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER‐2 overexpressors and random assignment to trastuzumab or not in HER‐2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 publication-title: J Clin Oncol – volume: 12 start-page: 350 year: 2010 end-page: 60 article-title: Trastuzumab emtansine, an antibody‐drug conjugate for the treatment of HER2+ metastatic breast cancer publication-title: Curr Opin Mol Ther – volume: 14 start-page: 320 year: 2009 end-page: 68 article-title: The HER‐2 receptor and breast cancer: ten years of targeted anti‐HER‐2 therapy and personalized medicine publication-title: Oncologist – volume: 18 start-page: 977 year: 2007 end-page: 84 article-title: Trastuzumab: mechanism of action, resistance and future perspectives in HER2‐overexpressing breast cancer publication-title: Ann Oncol – volume: 64 start-page: 2343 year: 2004 end-page: 6 article-title: The HER‐2‐targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells publication-title: Cancer Res – volume: 30 start-page: 1712 year: 2012 end-page: 4 article-title: Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy publication-title: J Clin Oncol – volume: 39 start-page: 260 year: 2009 end-page: 6 article-title: Phase I and pharmacokinetic study of HER2‐targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors publication-title: Jpn J Clin Oncol – volume: 110 start-page: 965 year: 2007 end-page: 72 article-title: Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study publication-title: Cancer – volume: 14 start-page: 2710 year: 2008 end-page: 6 article-title: Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2‐positive metastatic breast cancer publication-title: Clin Cancer Res – volume: 23 start-page: 1275 year: 2006 end-page: 84 article-title: Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis publication-title: Pharm Res – volume: 6 start-page: 204 year: 2004 end-page: 10 article-title: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors publication-title: Breast Cancer Res – volume: 15 start-page: 254 year: 1996 end-page: 64 article-title: ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer publication-title: EMBO J – volume: 28 start-page: 1131 year: 2010 end-page: 7 article-title: Open‐label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2‐negative metastatic breast cancer publication-title: J Clin Oncol – volume: 319 start-page: 1 year: 2004 end-page: 11 article-title: The ErbB/HER receptor protein‐tyrosine kinases and cancer publication-title: Biochem Biophys Res Commun – volume: 20 start-page: 719 year: 2002 end-page: 26 article-title: Efficacy and safety of trastuzumab as a single agent in first‐line treatment of HER2‐overexpressing metastatic breast cancer publication-title: J Clin Oncol – volume: 30 start-page: 1594 year: 2012 ident: 10.1002/phar.1338-BIB0038|phar1338-cit-0038 article-title: Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.37.4207 contributor: fullname: Cortes – volume-title: HERCEPTIN (Trastuzumab) injection for intravenous administration package insert year: 2010 ident: 10.1002/phar.1338-BIB0018|phar1338-cit-0018 contributor: fullname: Genentech Inc. – volume: 23 start-page: 2534 year: 2005 ident: 10.1002/phar.1338-BIB0031|phar1338-cit-0031 article-title: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.184 contributor: fullname: Agus – ident: 10.1002/phar.1338-BIB0040|phar1338-cit-0040 doi: 10.1158/0008-5472.SABCS12-P5-18-20 – volume: 14 start-page: 2710 year: 2008 ident: 10.1002/phar.1338-BIB0037|phar1338-cit-0037 article-title: Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4636 contributor: fullname: Portera – volume: 26 start-page: 3637 year: 2007 ident: 10.1002/phar.1338-BIB0003|phar1338-cit-0003 article-title: Trastuzumab: triumphs and tribulations publication-title: Oncogene doi: 10.1038/sj.onc.1210379 contributor: fullname: Nahta – volume: 20 start-page: 719 year: 2002 ident: 10.1002/phar.1338-BIB0020|phar1338-cit-0020 article-title: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.3.719 contributor: fullname: Vogel – volume: 319 start-page: 1 year: 2004 ident: 10.1002/phar.1338-BIB0014|phar1338-cit-0014 article-title: The ErbB/HER receptor protein-tyrosine kinases and cancer publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2004.04.150 contributor: fullname: Roskoski – volume: 9 start-page: 463 year: 2009 ident: 10.1002/phar.1338-BIB0006|phar1338-cit-0006 article-title: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 publication-title: Nat Rev Cancer doi: 10.1038/nrc2656 contributor: fullname: Baselga – volume: 5 start-page: 317 year: 2004 ident: 10.1002/phar.1338-BIB0007|phar1338-cit-0007 article-title: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex publication-title: Cancer Cell doi: 10.1016/S1535-6108(04)00083-2 contributor: fullname: Franklin – volume: 6 start-page: 204 year: 2004 ident: 10.1002/phar.1338-BIB0012|phar1338-cit-0012 article-title: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors publication-title: Breast Cancer Res doi: 10.1186/bcr919 contributor: fullname: Lin – volume: 366 start-page: 109 year: 2012 ident: 10.1002/phar.1338-BIB0039|phar1338-cit-0039 article-title: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1113216 contributor: fullname: Baselga – volume: 26 start-page: 1642 year: 2008 ident: 10.1002/phar.1338-BIB0021|phar1338-cit-0021 article-title: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.6699 contributor: fullname: Seidman – volume-title: TYKERB (Lapatinib) tablet for oral administration package insert year: 2012 ident: 10.1002/phar.1338-BIB0019|phar1338-cit-0019 contributor: fullname: GlaxoSmithKline – volume: 11 start-page: 793 year: 2011 ident: 10.1002/phar.1338-BIB0030|phar1338-cit-0030 article-title: Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications publication-title: Cancer Biol Ther doi: 10.4161/cbt.11.9.15045 contributor: fullname: Garrett – volume: 14 start-page: 320 year: 2009 ident: 10.1002/phar.1338-BIB0002|phar1338-cit-0002 article-title: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine publication-title: Oncologist doi: 10.1634/theoncologist.2008-0230 contributor: fullname: Ross – volume: 65 start-page: 473 year: 2005 ident: 10.1002/phar.1338-BIB0029|phar1338-cit-0029 article-title: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line publication-title: Cancer Res doi: 10.1158/0008-5472.473.65.2 contributor: fullname: Nagy – ident: 10.1002/phar.1338-BIB0046|phar1338-cit-0046 doi: 10.1158/0008-5472.SABCS11-S5-6 – volume: 28 start-page: 1138 year: 2010 ident: 10.1002/phar.1338-BIB0036|phar1338-cit-0036 article-title: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.2024 contributor: fullname: Baselga – volume: 2 start-page: 127 year: 2002 ident: 10.1002/phar.1338-BIB0035|phar1338-cit-0035 article-title: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth publication-title: Cancer Cell doi: 10.1016/S1535-6108(02)00097-1 contributor: fullname: Agus – volume: 25 start-page: 118 year: 2006 ident: 10.1002/phar.1338-BIB0001|phar1338-cit-0001 article-title: American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.2775 contributor: fullname: Wolff – volume: 110 start-page: 965 year: 2007 ident: 10.1002/phar.1338-BIB0022|phar1338-cit-0022 article-title: Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study publication-title: Cancer doi: 10.1002/cncr.22885 contributor: fullname: Burstein – volume-title: PERJETA (pertuzumab) injection for intravenous administration package insert year: 2012 ident: 10.1002/phar.1338-BIB0032|phar1338-cit-0032 contributor: fullname: Genentech Inc. – volume: 6 start-page: 219 year: 2004 ident: 10.1002/phar.1338-BIB0049|phar1338-cit-0049 article-title: Mammalian target of rapamycin (mTOR) antagonists publication-title: Breast Cancer Res doi: 10.1186/bcr927 contributor: fullname: Carraway – volume: 3 start-page: 379 year: 2004 ident: 10.1002/phar.1338-BIB0004|phar1338-cit-0004 article-title: Targeted therapy in breast cancer: the HER-2/neu gene and protein publication-title: Mol Cell Proteomics doi: 10.1074/mcp.R400001-MCP200 contributor: fullname: Ross – volume: 16 start-page: 5276 year: 1996 ident: 10.1002/phar.1338-BIB0015|phar1338-cit-0015 article-title: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor publication-title: Mol Cell Biol doi: 10.1128/MCB.16.10.5276 contributor: fullname: Tzahar – volume: 28 start-page: 1131 year: 2010 ident: 10.1002/phar.1338-BIB0041|phar1338-cit-0041 article-title: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.1661 contributor: fullname: Gianni – volume: 2 start-page: 127 year: 2001 ident: 10.1002/phar.1338-BIB0005|phar1338-cit-0005 article-title: Untangling the ErbB signalling network publication-title: Nature Rev Mol Cell Biol doi: 10.1038/35052073 contributor: fullname: Yarden – volume: 13 start-page: 25 year: 2012 ident: 10.1002/phar.1338-BIB0045|phar1338-cit-0045 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70336-9 contributor: fullname: Gianni – volume: 12 start-page: 350 year: 2010 ident: 10.1002/phar.1338-BIB0048|phar1338-cit-0048 article-title: Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer publication-title: Curr Opin Mol Ther contributor: fullname: Niculescu-Duvaz – ident: 10.1002/phar.1338-BIB0008|phar1338-cit-0008 doi: 10.1158/0008-5472.SABCS-09-5090 – volume: 30 start-page: 1712 year: 2012 ident: 10.1002/phar.1338-BIB0050|phar1338-cit-0050 article-title: Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2011.40.2545 contributor: fullname: Olson – ident: 10.1002/phar.1338-BIB0044|phar1338-cit-0044 doi: 10.1158/0008-5472.SABCS12-S5-1 – volume: 15 start-page: 254 year: 1996 ident: 10.1002/phar.1338-BIB0016|phar1338-cit-0016 article-title: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer publication-title: EMBO J doi: 10.1002/j.1460-2075.1996.tb00356.x contributor: fullname: Karunagaran – ident: 10.1002/phar.1338-BIB0011|phar1338-cit-0011 doi: 10.1158/0008-5472.SABCS-09-5060 – volume: 357 start-page: 39 year: 2007 ident: 10.1002/phar.1338-BIB0017|phar1338-cit-0017 article-title: Trastuzumab-mechanism of action and use in clinical practice publication-title: N Engl J Med doi: 10.1056/NEJMra043186 contributor: fullname: Hudis – volume: 23 start-page: 1275 year: 2006 ident: 10.1002/phar.1338-BIB0034|phar1338-cit-0034 article-title: Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis publication-title: Pharm Res doi: 10.1007/s11095-006-0205-x contributor: fullname: Ng – volume: 64 start-page: 361 year: 2009 ident: 10.1002/phar.1338-BIB0023|phar1338-cit-0023 article-title: Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-008-0882-8 contributor: fullname: Ishida – ident: 10.1002/phar.1338-BIB0043|phar1338-cit-0043 doi: 10.1158/0008-5472.SABCS12-P5-18-26 – volume: 28 start-page: 1301 year: 2010 ident: 10.1002/phar.1338-BIB0010|phar1338-cit-0010 article-title: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.8707 contributor: fullname: Burstein – volume: 93 start-page: 1852 year: 2001 ident: 10.1002/phar.1338-BIB0027|phar1338-cit-0027 article-title: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) publication-title: J Natl Cancer Inst doi: 10.1093/jnci/93.24.1852 contributor: fullname: Lu – volume: 421 start-page: 756 year: 2003 ident: 10.1002/phar.1338-BIB0033|phar1338-cit-0033 article-title: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab publication-title: Nature doi: 10.1038/nature01392 contributor: fullname: Cho – volume: 20 start-page: 41 year: 1998 ident: 10.1002/phar.1338-BIB0013|phar1338-cit-0013 article-title: Specificity within the EGF family/ErbB receptor family signaling network publication-title: BioEssays doi: 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V contributor: fullname: Riese – ident: 10.1002/phar.1338-BIB0024|phar1338-cit-0024 – volume: 6 start-page: 117 year: 2004 ident: 10.1002/phar.1338-BIB0026|phar1338-cit-0026 article-title: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients publication-title: Cancer Cell doi: 10.1016/j.ccr.2004.06.022 contributor: fullname: Nagata – volume: 28 start-page: 1124 year: 2010 ident: 10.1002/phar.1338-BIB0009|phar1338-cit-0009 article-title: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.21.4437 contributor: fullname: Blackwell – volume: 18 start-page: 977 year: 2007 ident: 10.1002/phar.1338-BIB0025|phar1338-cit-0025 article-title: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdl475 contributor: fullname: Valabrega – volume: 23 start-page: 791 year: 2012 ident: 10.1002/phar.1338-BIB0047|phar1338-cit-0047 article-title: Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab publication-title: Ann Oncol doi: 10.1093/annonc/mdr294 contributor: fullname: Lenihan – volume: 39 start-page: 260 year: 2009 ident: 10.1002/phar.1338-BIB0042|phar1338-cit-0042 article-title: Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyp006 contributor: fullname: Yamamoto – volume: 64 start-page: 2343 year: 2004 ident: 10.1002/phar.1338-BIB0028|phar1338-cit-0028 article-title: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-3856 contributor: fullname: Nahta |
| SSID | ssj0021642 |
| Score | 2.1999474 |
| SecondaryResourceType | review_article |
| Snippet | Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor‐2... Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor-2... |
| SourceID | proquest crossref pubmed pascalfrancis wiley istex |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 60 |
| SubjectTerms | Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Agents - administration & dosage Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - secondary Cancer therapies Clinical trials Clinical Trials as Topic - trends Drug Delivery Systems - trends Drug therapy Female Gynecology. Andrology. Obstetrics HER2 human epidermal growth factor receptor Humans Mammary gland diseases Medical sciences Metastasis Multiple tumors. Solid tumors. Tumors in childhood (general aspects) pertuzumab Pharmacology. Drug treatments Receptor, ErbB-2 - genetics Treatment Outcome Tumors |
| Title | Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer |
| URI | https://api.istex.fr/ark:/67375/WNG-XBSDGPJC-L/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fphar.1338 https://www.ncbi.nlm.nih.gov/pubmed/23918291 https://www.proquest.com/docview/1565515998 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwED_BeOGF_7CMMVkIVTwszLGdJoGnrutWIRjRVsTeLNuxBUIrU9IiyhMfgc_IJ8HntKkqgYTEWx58SnJn3_1-9t0Z4Fmi0swxk8dIgGJROBOrXInYYuwxwtFKIVEcn2enF_nRCNvkvFrVwrT9IboNN1wZwV_jAle6OVg3Db36qOoXyLC8__UsIZRv8LIjW54GhBMEPKLEQLfqKkTZQSe5EYtuoFq_YW6karx6XHuvxZ-A5yaODYHo-PZ__cIduLXEn2TQTpi7cM1O70GvbBtYL_bJZF2P1eyTHinXra0X9-FdaevZ_Pv8UumXZEC8hySTkEpuq6XkgngUTMajM_brx88yZIR9teStnSksXfpkyCFmwc_IEGdb_QDeH48mw3G8vJIhNsKDgVjgsR_lvPJh3elKeE9pkFRSS5lzuRaV0dwpqrXHJVRpQ01iK9rXHubkiWP8IWxNv0ztNhCeO1W4IrVap8KTUp1VRoiMq75wrF-oCJ6ujCOv2s4bsu2xzCQqTqLiIugFs3UjVP0ZU9WyVH44PZEXh-dHJ-XroXwTwd6GXTsBlidpxjiPYHdlaLlcxo305DZFwFf4Fz1qjb8W5IXnZkUSwfNg479_pCzHgzN82Pn3oY_hpodmot3s2YWtWT23T-B6U833wjz_De2R_qc |
| link.rule.ids | 315,782,786,1408,4028,27932,27933,27934,46064,46488 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwED-x7QFexv8tMIaFUMXDwpzYaRLES9d1C9CVaOvE3izbsbVpokxpiyhPfAQ-I58EX9KmqgQSEm958CnJ3dn3-9l3Z4CXgYxiG-rERwLk89RqXyaS-wZjj-aWFhKJYnYWDy6Swx62yXm7qIWp-0M0G244M6r1Gic4bkjvL7uG3lzK8jVSrDXY4G3niFjAwfKGbjkiUJ0h4CElhrpFXyEa7jeiK9FoAxX7DbMj5dgpyNY3W_wJeq4i2SoUHd39v5-4B5tzCEo6tc_ch1tm9ABaed3DerZHhsuSrPEeaZF82d169hA-5qacTL9PP0v1hnSIWyTJsMomN8VcckYcECZZ7zT89eNnXiWFfTXkxEwkVi9daXKAifAT0kWHKx_B-VFv2M38-a0MvuYOD_gcT_4oY4WL7FYV3C2WGnklNTS0NlG80IpZSZVy0IRKpakOTEHbyiGdJLAhewzroy8jsw2EJVamNo2MUhF3vFTFheY8ZrLNbdhOpQcvFtYRN3XzDVG3WQ4FKk6g4jxoVXZrRsjyGrPV4kh8GhyLi4Ozw-P8fVf0PdhdMWwjECZBFIeMebCzsLSYz-SxcPw2QsyXuhdt1dZfCrLU0bM08OBVZeS_f6TIs84pPjz596HP4XY2POmL_rvBh6dwxyE1Xu_97MD6pJyaZ7A2Lqa7ldP_BvwdAt4 |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xuxLiwvsRWBYLoYrDhnVip0ng1O1jCywl2i1ib5afAiFKlbaIcuIn8Bv5JXiSNlUlkJC45eBRkhnb8332-DPAk0gmqYt1FiIBCnnudCgzyUOLuUdzR41Eojg8T0cXWa-PMjkv1mdhan2IZsENR0Y1X-MAnxp3tBENnX6Q5TNkWDuwxz0MR-F8xoqGbXkeUG0h4B4lZrq1rBCNjxrTrWS0h379hsWRcub94-qLLf6EPLeBbJWJBtf-6x-uw9UVACWdusfcgEt2chNaRa1gvTwk482BrNkhaZFio229vAVvC1vOF98Xn6V6TjrET5FkXNWSW7OyXBIPg8mwfxb_-vGzqErCvlryxs4lnl36qMkxlsHPSRe7W3kb3g364-4wXN3JEGru0UDIcd-PMmZ8XnfKcD9VamSV1NLYuUxxoxVzkirlgQmVSlMdWUPbyuOcLHIxuwO7ky8Tew8Iy5zMXZ5YpRLuWalKjeY8ZbLNXdzOZQCP18ER01p6Q9Qiy7FAxwl0XACtKmxNC1l-wlq1NBHvRyfi4vi8d1K86orTAA624toYxFmUpDFjAeyvAy1W43gmPLtNEPHl_kV36-BvDFnuyVkeBfC0ivHfP1IUw84ZPtz_96aP4HLRG4jTl6PXD-CKh2m8XvjZh915ubAPYWdmFgdVl_8N12kBhA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pertuzumab%3A+A+New+Targeted+Therapy+for+HER2-Positive+Metastatic+Breast+Cancer&rft.jtitle=Pharmacotherapy&rft.au=MALENFANT%2C+Stephanie+J&rft.au=ECKMANN%2C+Karen+R&rft.au=BARNETT%2C+Chad+M&rft.date=2014&rft.pub=Pharmacotherapy&rft.issn=0277-0008&rft.eissn=1875-9114&rft.volume=34&rft.issue=1&rft.spage=60&rft.epage=71&rft_id=info:doi/10.1002%2Fphar.1338&rft.externalDBID=n%2Fa&rft.externalDocID=28157233 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0277-0008&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0277-0008&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0277-0008&client=summon |